SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
13.66
-1.20 (-8.08%)
At close: Nov 20, 2026, 4:00 PM EST
14.26
+0.60 (4.36%)
After-hours: Nov 20, 2026, 7:59 PM EST
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
2.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.00M | -6.60M | -86.84% |
| Dec 31, 2021 | 7.60M | 5.70M | 300.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.36B |
| Acadia Pharmaceuticals | 1.20B |
| Telix Pharmaceuticals | 890.79M |
| ADMA Biologics | 519.15M |
| Iovance Biotherapeutics | 378.98M |
| Vericel | 324.17M |
| Denali Therapeutics | 21.38M |
SLS News
- 20 hours ago - SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 1 day ago - SELLAS Life Sciences Group Slides: Corporate presentation - Filings
- 2 days ago - Sellas Life Sciences falls -18.3% - TheFly
- 2 days ago - Sellas Life Sciences falls -13.8% - TheFly
- 2 days ago - SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering - GlobeNewsWire
- 3 days ago - Sellas Life Sciences announces $150M common stock offering - TheFly
- 3 days ago - SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering - GlobeNewsWire
- 3 days ago - Sellas Life Sciences price target raised to $40 from $30 at Maxim - TheFly